
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is making strides in its YARTEMLEA launch, with positive feedback from physicians, significant institutional access secured, and promising pediatric uptake. Its pipeline also provides additional potential, with OMS1029 and OMS527 both advancing to Phase 2 and promising results from its OncotoX-AML and T-CAT platform programs. Coupled with its strong financial profile and positive outlook for reimbursement and market uptake, Omeros appears to have a solid path to positive cash flow and continued growth. However, there are still risks to consider, such as clinical, regulatory, financial, commercial, and legal and intellectual property factors, which could impact its overall performance.
Bears say
Omeros is a high-risk investment, with regulatory, clinical development, commercialization, intellectual property, and pipeline development risks. While Omeros's pipeline shows potential with a regulatory decision on YARTEMLEA expected in mid-2026 and upcoming earnings calls, its financials and management's commentary on commercial infrastructure will be crucial factors to monitor as the company moves forward.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares